Targeting PHF20L1 or its related pathways, such as combining DNMT1 and G9a/GLP inhibitors, may be an effective strategy to reverse chemotherapeutic resistance and enhance the effectiveness of cancer treatments. Here, PHF20L1 is linked to cancer.